RAC
Director Trades
| Date | Director | Value |
|---|
Company News
Race Oncology Identifies Breakthrough Anticancer Mechanism for Bisantrene (RCDS1)
Race Oncology (ASX: RAC) has discovered the primary anticancer mechanism of action for its lead drug candidate (E,E)-bisantrene, also known as RCDS1. New studies show the compound acts by binding to special DNA and RNA structures called G-quadruplexes, or G4s, which regulate many cancer-driving genes including the master switch MYC. Chief executive officer Dr Daniel Tillett […]
Race Oncology’s bisantrene RC220 AML treatment earns coveted FDA orphan drug designation
Race Oncology (ASX: RAC) has achieved a significant breakthrough with the US Food and Drug Administration (FDA) awarding orphan drug designation (ODD) to the company’s acute myeloid leukemia (AML) candidate bisantrene RC220. The coveted designation qualifies Race for various benefits including tax credits, fee exemptions, market exclusivity and regulatory assistance from the FDA throughout the […]
Race Oncology heads into 2022 with extra $29.7m in bank to advance lead drug Zantrene
Race Oncology (ASX: RAC) is closing out 2021 with an extra $29.7 million in the bank after completing a heavily oversubscribed share purchase plan that saw almost $44 million in applications. Under the share purchase plan, eligible existing Race shareholders were offered the company’s stock at $3 each. The company has accepted $29.7 million of those […]
Published study highlights ‘superior efficacy’ of Race Oncology’s Zantrene combined with other cancer drugs
Race Oncology (ASX: RAC) has announced the publication of a peer-reviewed pre-clinical study that has identified additional drug combinations showing synergy with its cancer-fighting drug Zantrene when tested in acute myeloid leukaemia (AML) cells. The Race Oncology-sponsored paper entitled “Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukaemia […]
Race Oncology confirms lead drug Zantrene has cardio-protective properties during cancer treatment
Specialty pharmaceutical company Race Oncology (ASX: RAC) has found its lead candidate Zantrene (bisantrene dihydrochloride) is able to protect heart muscles from cell death caused by chemotherapy drug carfilzomib. Results from a preclinical heart safety research program, led by cardiotoxicity researchers at the University of Newcastle, showed that Zantrene protects heart muscle cells from a […]
Race Oncology expands Zantrene heart-protective research with University of Newcastle
After identifying its heart protective effects, Race Oncology (ASX: RAC) has extended the collaboration with the University of Newcastle for its Zantrene (bisantrene dihydrochloride) anti-cancer drug. Earlier this week, Race revealed preclinical research using Zantrene has shown it can synergise with chemotherapy drug carfilzomib and improve cancer cell death, while also providing protection against heart […]
Race Oncology seeks cash to advance anti-cancer and heart protection drug
Precision oncology company Race Oncology (ASX: RAC) is looking to raise capital to enable the execution of its expanded business strategy and to progress the clinical program of its anti-cancer drug Zantrene following a recent breakthrough discovery. The company has opened a share purchase plan to raise up to $29.7 million to fund a number […]
Race Oncology begins preparing for clinical breast cancer trials using bisantrene
Race Oncology (ASX: RAC) has unveiled what it describes as “impressive” results in preclinical breast cancer research using its bisantrene drug. The company undertook a collaborative preclinical research program with The University of Newcastle in New South Wales, with Hunter Medical Research Institute associate professor Nikki Verrills leading the project. During the study, bisantrene was […]
Race Oncology confirms positive results from Bisantrene drug trial on patients with advanced acute myeloid leukaemia
Specialty pharmaceutical company Race Oncology (ASX: RAC) has reported positive data from an investigator-initiated Phase II clinical trial of historical cancer drug Bisantrene on patients with relapsed or refractory acute myeloid leukaemia. Conducted at the Sheba Medical Centre in Israel, the open-label, single-agent trial studied 10 patients who, on average, had failed three prior lines […]
Race Oncology raises $1.8m to advance ‘five-path’ strategy for cancer drug Bisantrene
Pharmaceutical company Race Oncology (ASX: RAC) has come out of a trading halt this morning to announce $1.8 million new equity funding via a strategic placement of 6 million shares. The $0.30 per share issue price represents a 9% discount to the company’s last closing price and a 9.5% discount to the 20-trading day volume-weighted […]
